Lexeo Therapeutics, Inc. financial data

Symbol
LXEO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
345 Park Avenue South, Floor 6, New York, NY
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 733 %
Debt-to-equity 20.2 %
Return On Equity -65.1 % -179%
Return On Assets -54.2 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.2M shares +24.5%
Common Stock, Shares, Outstanding 33.1M shares +24.1%
Entity Public Float 528M USD
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 31.8M shares +494%
Weighted Average Number of Shares Outstanding, Diluted 31.8M shares +494%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 74.1M USD +39.5%
General and Administrative Expense 31.7M USD +106%
Operating Income (Loss) -106M USD -54.4%
Nonoperating Income (Expense) 7.43M USD +251%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -98.3M USD -48.1%
Net Income (Loss) Attributable to Parent -98.3M USD -48.1%
Earnings Per Share, Basic -3.09 USD/shares +75.1%
Earnings Per Share, Diluted -3.09 USD/shares +75.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35M USD -71.2%
Cash, Cash Equivalents, and Short-term Investments 129M USD
Other Assets, Current 3K USD -99.2%
Assets, Current 126M USD +1.47%
Property, Plant and Equipment, Net 1.03M USD -2.65%
Operating Lease, Right-of-Use Asset 8.07M USD -14.5%
Assets 147M USD +5.1%
Accounts Payable, Current 6.42M USD +69.1%
Liabilities, Current 22.8M USD +32.5%
Operating Lease, Liability, Noncurrent 6.44M USD -17.3%
Liabilities 30.1M USD +14.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -103K USD
Retained Earnings (Accumulated Deficit) -280M USD -54.1%
Stockholders' Equity Attributable to Parent 117M USD +2.91%
Liabilities and Equity 147M USD +5.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.9M USD +19.1%
Net Cash Provided by (Used in) Financing Activities 88.7M USD
Net Cash Provided by (Used in) Investing Activities -193K USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 33.1M shares +24%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 73.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 38.3M USD -69.3%
Deferred Tax Assets, Valuation Allowance 95.4M USD +54%
Deferred Tax Assets, Gross 98.4M USD +50.6%
Operating Lease, Liability 8.54M USD -13.5%
Payments to Acquire Property, Plant, and Equipment 185K USD
Lessee, Operating Lease, Liability, to be Paid 10.3M USD -17%
Property, Plant and Equipment, Gross 1.5M USD +4.52%
Operating Lease, Liability, Current 2.1M USD +0.62%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.21M USD +2.51%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.15M USD +1.89%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.77M USD -30.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.26M USD +2.49%
Deferred Tax Assets, Operating Loss Carryforwards 33.3M USD +52%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.32M USD +2.52%
Operating Lease, Payments 2.11M USD -8.02%
Deferred Tax Assets, Net of Valuation Allowance 2.98M USD -11.5%
Share-based Payment Arrangement, Expense 12.5M USD +310%
Interest Expense 174K USD -34%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%